Prostate cancer (PCa) is the most common non-skin malignancy and the cancer second most responsible for death in men in United States. Prior studies with animal models of PCa and with humans demonstrated that the prostate produces various growth factors. Addition or blocking of these factors alters PCa cell proliferation and other functions. Among these factors, transforming growth factor-?1 (TGF-?) is involved in tumorigenicity, displays potent immunosuppressive activities, and is required for the conversion of conventional CD4+ T cells to FoxP3+ regulatory T (TR) cells. TR cells that express the transcription factor Foxp3 are essential for normal immune function;absence of TR cells results in multi-organ autoimmunity and death. A clear role of TGF-? and its effect on TR during PCa development and progression lacks experimental evidence. In this proposal, we plan to investigate the underlying mechanisms involved in the context of TGF-? and/or TR using PCa cell lines, derived from transgenic mouse for prostate cancer (TRAMP), in C57/B6 mice. Of these cell lines, TRAMP- C1 and TRAMP-C2 form tumors;TRAMP-C3 fails to do so. These mouse cell lines of PCa can be used to obtain the long-term goal of this project, which is to address the fundamental question: Do TR cells and/or TGF-? levels relate to differences in tumorigenicity of the TRAMP cell lines (C1, C2, and C3)? The objective of this project is to define the role of TGF-? production by host cells in response to or TGF-? expression by TRAMP cell lines and to establish the function of TGF-? on the conversion of naive CD4+ T cells into Foxp3-expressing TR cells.

Public Health Relevance

Prostate Cancer is the most common non-skin malignancy and commonly diagnosed cancer, and second most cancer responsible for death in men in United States. To limit the prostate cancer frequency and to expedite the treatment measures, it is important to understand the underlying mechanisms involved during prostate cancer development and progression. Studies in this proposal will help to understand the mechanisms involved during prostate cancer in the context of Transforming Growth Factor- and regulatory T cell-control of anti- tumor immune responses that are essential to the rationale design of tumor vaccines and adoptive immunotherapy of future.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory Grants (P20)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-PCRB-C (O1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Alabama State University
United States
Zip Code
Kumar, Sanjay; Stokes 3rd, James; Singh, Udai P et al. (2016) Targeting Hsp70: A possible therapy for cancer. Cancer Lett 374:156-66
de Aquino, Maria Teresa P; Malhotra, Anshu; Mishra, Manoj K et al. (2015) Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 166:117-33